Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1-14. (cancelled)

15. (new) A pharmaceutical composition for sublingual, buccal or enteric administration comprising one or more substances obtainable by hydrolysis with chymotrypsin or any other protease of an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease.

16. (new) The pharmaceutical composition of claim 15 wherein the amount of said substance is in the range of 0.001 to 1000 μg.

17. (new) The pharmaceutical composition of claim 16 wherein the amount of said substance is in the range of 1 to 100 μg.

18. (new) The pharmaceutical composition of claim 15 wherein said substance is obtainable by hydrolysis of a protein.

19. (new) The pharmaceutical composition of claim 15 wherein said substance is a peptide.

20. (new) The pharmaceutical composition of claim 19 wherein the peptide has a molecular weight of less than 30 kDa.

21. (new) The pharmaceutical composition of claim 20 wherein the peptide has a molecular weight of less than 10 kDa.

22. (new) The pharmaceutical composition of claim 15 comprising additionally one or more substances selected from nucleoside triphosphates, nucleoside diphosphates,

nucleoside monophosphates, nucleic acids, peptide nucleic acids, nucleosides or analogs thereof, immunosuppressive cytokines, compounds inducing expression of immunoproteasomes, 1,25-dihydroxyvitamin D3 or analogs thereof, lipopolysaccharides, endotoxins, heat shock proteins, thioredoxin with either NADPH or NADP-thioredoxin reductase, dithiothreitol, adrenergic receptor agonists such as salbutanol, adrenergic receptor antagonists such as butoxamine, compounds that regulate the expression of the adhesion molecule ICAM-1, N-acetyl-L-cysteine, y-L-glutamyl-L-cysteinyl-glycine (reduced L-glutathione), alpha-2-macroglobulins, inducers for Foxp3 gene expression, flavonoids, isoflavonoids, pterocarpanoids, stilbenes such as resveratrol, tachykinin receptor antagonists, chymase inhibitors, a muco-adhesive agent for attaching the particle to the intestinal mucosal lining such as a plant lectin, zinc, zinc salts, polysaccharides, vitamins and bacterial lysates.

23. (new) The pharmaceutical composition of claim 15 wherein the antigenic structure is selected from insulin, thyroglobulin, thyroid peroxidase, type II collagen, gliadin, GAD65, proteolipid protein, S-antigen, acetylcholin receptor, haptenized colonic proteins, interphotoreceptor retinoid binding protein, myelin basic protein, myelin oligodendrocyte glycoprotein, peripheral nerve P2, cytoplasmic TSH receptor, intrinsic factor, lens proteins, platelets, nucleoproteins such as histones, heat shock proteins, MHC I, MHC II, MHC-peptide complexes, milk allergens, venom allergens, egg allergens, weed allergens, grass allergens, tree allergens, shrub allergens, flower allergens, grain allergens, fungi allergens, fruit allergens, berry allergens, nut allergens, seed allergens, bean allergens, fish allergens, shellfish allergens, meat allergens, spices

allergens, insect allergens, mite allergens, animal allergens, animal dander allergens, allergens of Hevea brasiliensis, coagulation factors and blood group antigens.

24. (new) A method for the treatment or prevention of graft rejection, allergic reaction or autoimmune disease in a mammal comprising administering to said mammal the pharmaceutical composition of claim 15.

25. (new) A method for eliciting oral tolerance or the induction of cells that may produce immunosuppressive cytokines selected from the group consisting of TGF-beta, IL-4 and IL-10 in a mammal, comprising administering to said mammal the pharmaceutical composition of claim 15.

26. (new) A process for the preparation of the pharmaceutical composition of claim 15 comprising:

(a) hydrolyzing with chymotrypsin or any other protease an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease to obtain at least one substance; and

(b) formulating the at least one substance for enteric, sublingual or enteric administration.

27. (new) The pharmaceutical composition of claim 15 in a sublingual formulation.

28. (new) The pharmaceutical composition of claim 15 in a buccal formulation.

29. (new) The pharmaceutical composition of claim 15 in an enteric formulation.